The company stated that the European Union medicines regulator recommended a marketing authorization for the company’s drug Prevymis to treat a type of infection in adult kidney transplant recipients at high risk.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-signs-1.2-bln-deal-for-1.7-mln-courses-of-Mercks-experimental-COVID-19-drug-Reuters-6-9-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-10-17 07:29:482023-10-17 09:22:37EU regulator backs use of Merck's viral infection drug
